Your browser is no longer supported. Please, upgrade your browser.
AGLE Aeglea BioTherapeutics, Inc. daily Stock Chart
AGLE [NASD]
Aeglea BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-2.42 Insider Own1.20% Shs Outstand33.10M Perf Week1.97%
Market Cap381.83M Forward P/E- EPS next Y-1.95 Insider Trans46.47% Shs Float42.93M Perf Month16.53%
Income-79.80M PEG- EPS next Q-0.45 Inst Own53.00% Short Float0.59% Perf Quarter28.99%
Sales- P/S- EPS this Y-15.00% Inst Trans-0.15% Short Ratio1.43 Perf Half Y3.89%
Book/sh1.29 P/B6.83 EPS next Y1.70% ROA-87.30% Target Price- Perf Year35.12%
Cash/sh1.13 P/C7.79 EPS next 5Y- ROE-113.10% 52W Range3.50 - 9.38 Perf YTD15.31%
Dividend- P/FCF- EPS past 5Y-22.00% ROI- 52W High-6.08% Beta2.07
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low151.71% ATR0.65
Employees79 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)65.57 Volatility5.79% 8.70%
OptionableYes Debt/Eq0.00 EPS Q/Q4.40% Profit Margin- Rel Volume0.80 Prev Close8.90
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume177.66K Price8.81
Recom2.20 SMA2010.23% SMA5040.41% SMA20020.02% Volume142,374 Change-1.01%
May-04-20Initiated Piper Sandler Overweight $12
Mar-21-19Initiated JP Morgan Overweight $14
Sep-04-18Downgrade Wells Fargo Outperform → Market Perform
Apr-24-18Initiated Evercore ISI Outperform $37
Mar-14-18Reiterated Needham Buy $8 → $12
May-29-20 11:49AM  Aeglea BioTherapeutics' Shares March Higher, Can It Continue? Zacks
May-28-20 04:10PM  Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020 GlobeNewswire
May-27-20 08:43AM  Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1% Zacks
May-26-20 08:30AM  Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology GlobeNewswire
May-21-20 11:30AM  Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year? Zacks
May-20-20 08:56AM  Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources Zacks
May-19-20 07:26PM  Find Strong Stocks During the Coronavirus with New Analyst Coverage Zacks +7.82%
10:10AM  4 Stocks in the Limelight on New Analyst Coverage Zacks
08:30AM  Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology GlobeNewswire
May-07-20 08:41AM  Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now? Zacks +5.50%
08:30AM  Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights GlobeNewswire
May-06-20 09:31AM  Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue? Zacks -7.90%
06:19AM  Anthony Quinn Is The President of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) And They Just Picked Up 44% More Shares Simply Wall St.
May-05-20 12:00PM  Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Apr-30-20 04:05PM  Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-28-20 09:07AM  Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering GlobeNewswire +28.02%
Apr-27-20 04:01PM  Aeglea BioTherapeutics Announces Proposed Public Offering GlobeNewswire
Apr-08-20 07:30AM  Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) GlobeNewswire +7.42%
Mar-29-20 08:31AM  Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price? Simply Wall St.
Feb-24-20 07:30AM  Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones GlobeNewswire -5.72%
Feb-13-20 05:37AM  Should Aeglea BioTherapeutics (NASDAQ:AGLE) Be Disappointed With Their 66% Profit? Simply Wall St.
Jan-13-20 07:00AM  Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) GlobeNewswire
Jan-08-20 05:11AM  Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified? Simply Wall St.
Jan-06-20 04:05PM  Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-12-19 07:08PM  Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE) Insider Monkey
Dec-03-19 05:22AM  Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their Holdings Simply Wall St.
Nov-26-19 08:30AM  Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-06-19 08:30AM  Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Nov-04-19 08:30AM  Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer GlobeNewswire
Oct-10-19 08:54AM  Will Aeglea BioTherapeutics (NASDAQ:AGLE) Spend Its Cash Wisely? Simply Wall St.
Sep-04-19 11:22AM  Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price? Simply Wall St.
Sep-03-19 06:00AM  Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium GlobeNewswire
Aug-29-19 08:30AM  Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium GlobeNewswire
Aug-06-19 08:00AM  Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Jul-25-19 07:21AM  The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug Benzinga +19.58%
Jul-24-19 04:05PM  Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency GlobeNewswire
Jul-17-19 03:47PM  Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register? Simply Wall St.
Jun-14-19 08:15PM  Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of Shares GuruFocus.com
Jun-11-19 07:37PM  Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE) Insider Monkey
Jun-03-19 08:30AM  Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency GlobeNewswire
May-30-19 08:30AM  Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences GlobeNewswire
May-24-19 10:30AM  These 3 Biotech Stocks Are Attracting Insider Buying TheStreet.com
May-22-19 07:15PM  Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of Shares GuruFocus.com
May-07-19 07:51AM  Aeglea: 1Q Earnings Snapshot Associated Press
07:45AM  Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Apr-27-19 09:11AM  Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares? Simply Wall St.
Apr-08-19 10:30AM  Aeglea (AGLE) Reports New Positive Data for Pegzilarginase Zacks -7.75%
Apr-07-19 07:15PM  Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders GlobeNewswire
Apr-01-19 08:00AM  Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders GlobeNewswire
Mar-28-19 08:30AM  Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-12-19 05:41PM  Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-19 12:44AM  Aeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-07-19 04:05PM  Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights GlobeNewswire
Mar-06-19 01:41PM  The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On Simply Wall St.
Feb-28-19 08:00AM  Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call GlobeNewswire
Feb-07-19 09:12AM  Aeglea aims to raise $60M for treating rare diseases American City Business Journals
Feb-06-19 12:15AM  Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering GlobeNewswire -19.15%
Feb-05-19 05:15PM  Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-29-19 09:57AM  How Much Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Do Institutions Own? Simply Wall St.
Jan-02-19 09:09AM  Austin's top-performing stocks of 2018 American City Business Journals +7.34%
Dec-23-18 07:52AM  Is Aeglea BioTherapeutics, Inc. (AGLE) A Good Stock To Buy? Insider Monkey
Dec-14-18 12:59PM  What Investors Should Know About Aeglea BioTherapeutics, Inc.s (NASDAQ:AGLE) Financial Strength Simply Wall St.
Dec-11-18 04:05PM  Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency GlobeNewswire
Dec-06-18 04:05PM  Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference GlobeNewswire -5.30%
Nov-20-18 08:00AM  Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference GlobeNewswire
Nov-14-18 07:45AM  Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-08-18 09:12AM  Aeglea: 3Q Earnings Snapshot Associated Press
08:00AM  Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Oct-26-18 08:00AM  Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting GlobeNewswire
Oct-22-18 08:00AM  Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress GlobeNewswire
Oct-19-18 08:00AM  Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference GlobeNewswire -6.06%
Oct-17-18 07:00AM  Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency GlobeNewswire
Oct-10-18 08:00AM  Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting GlobeNewswire -7.05%
Oct-01-18 08:00AM  FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency GlobeNewswire
Sep-28-18 02:14PM  Is Now The Right Time To Invest In Healthcare And Aeglea BioTherapeutics Inc (NASDAQ:AGLE)? Simply Wall St.
Sep-17-18 08:00AM  Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology GlobeNewswire
Sep-04-18 03:03PM  Aeglea Plunges On Updated Data For Arginase 1 Deficiency Candidate, Wells Fargo Downgrade Benzinga -15.46%
Aug-28-18 08:00AM  Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-27-18 08:00AM  Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium GlobeNewswire
Aug-20-18 09:00AM  George Soros Bought This Under-the-Radar Biotech Stock: Should You? Motley Fool
Aug-09-18 08:38AM  Aeglea: 2Q Earnings Snapshot Associated Press +5.86%
08:00AM  Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 04:00PM  Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule GlobeNewswire
Jul-19-18 04:00PM  Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer GlobeNewswire
Jul-16-18 08:00AM  Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors GlobeNewswire
Jul-03-18 03:27PM  Alkermes' Aristada Initio Approved by FDA for Schizophrenia Zacks -5.55%
Jun-29-18 04:00PM  Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-25-18 09:12AM  Novo Nordisk (NVO) Announces Results in Diabetes Studies Zacks
Jun-21-18 04:14PM  Anika Reports Top Line Data from CINGAL Study, Shares Slump Zacks
Jun-20-18 05:51PM  Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs Zacks
05:03PM  Alexion (ALXN) Submits Application for ALXN1210 with FDA Zacks
03:54AM  Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug Zacks
Jun-15-18 02:00PM  Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone Zacks
Jun-14-18 05:55PM  Flex Pharma Down on Workforce Reduction, Ends Phase II Study Zacks
04:44PM  Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA Zacks
10:50AM  BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity Benzinga
May-31-18 11:23AM  5 Biotech Stocks to Boost Your Portfolios Health This Year InvestorPlace
May-15-18 08:00AM  Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference GlobeNewswire
May-08-18 08:13AM  Aeglea: 1Q Earnings Snapshot Associated Press
08:00AM  Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results GlobeNewswire
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quinn Anthony G.President & CEOApr 30Buy4.75165,000783,750538,469May 04 07:30 AM
Quinn Anthony G.President & CEOOct 04Option Exercise6.2818,265114,689371,908Oct 07 04:09 PM
Quinn Anthony G.President & CEOJun 14Buy6.235,28232,913353,643Jun 14 05:22 PM
Quinn Anthony G.President & CEOJun 13Buy6.1714,40688,836348,361Jun 14 05:22 PM
Quinn Anthony G.President & CEOJun 12Buy6.1112,21774,705333,955Jun 14 05:22 PM